drugset / Trial / NCT06199973
Injection of SHR-A1811 Versus Physician Choiced Treatment in Patients With Advanced Colorectal Cancer Who Had Failed to Respond to Oxaliplatin, 5-fu, and Irinotecan
RandomizedParallel-groupOpen-labelTreatment
Summary
The study is being conducted to evaluate the efficacy, and safety of SHR-A1811 in advanced colorectal cancer subjects.
Timeline
- Start
- 2024-03-01
- Primary completion
- 2026-04
- Completion
- 2026-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Fruquintinib | Small molecule | 5 mg | — |
| Subject | Regorafenib | Small molecule | 160 mg | — |
| Subject | TAS-102 | Small molecule | 35 mg/m2 | — |
| Subject | Trastuzumab Rezetecan | Monoclonal antibody | 4.8 mg/kg | Intravenous |